Related Experiment Videos
Platelet activating factor receptor blockade ameliorates murine systemic lupus erythematosus
E Baldi1, S N Emancipator, M O Hassan
1Department of Medicine, Case Western Reserve University, Cleveland, Ohio.
Kidney International
|December 1, 1990
Summary
Platelet activating factor (PAF) contributes to lupus nephritis in mice. Blocking the PAF receptor reduced kidney inflammation, proteinuria, and improved renal function, suggesting therapeutic potential.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- MRL/MpJ-lpr/lpr mice exhibit lupus nephritis, characterized by kidney dysfunction.
- Platelet activating factor (PAF) is a proinflammatory mediator implicated in inflammatory diseases.
Purpose of the Study:
- To investigate the role of PAF in murine lupus nephritis.
- To evaluate the therapeutic effect of a PAF receptor antagonist on lupus nephritis.
Main Methods:
- Assessed renal PAF synthesis in lupus-prone (lpr) and control (+/+) mice.
- Treated lpr mice with PAF receptor antagonist L659,989 from 12 to 16 weeks of age.
- Evaluated kidney histology, proteinuria, and serum creatinine levels.
Main Results:
- Lupus mice showed increased renal PAF production compared to controls.
- L659,989 treatment significantly reduced glomerular infiltration, proliferation, and chronic damage.
- Proteinuria and serum creatinine levels were significantly decreased in treated mice.
- Treatment normalized renal PAF synthesis in lpr mice.
Conclusions:
- PAF is a key mediator in the development of glomerular injury in murine lupus nephritis.
- PAF receptor antagonists demonstrate therapeutic potential for treating lupus nephritis and other immune-related kidney diseases.